Search
for
Sort by
Research 751–780 of 764
- Advances in mitochondria-centered mechanism behind the roles of androgens and androgen receptor in the regulation of glucose and lipid metabolism
- Neuroendocrine, Neurotransmitter, and Gut Microbiota Imbalance Contributing to Potential Psychiatric Disorder Prevalence in PCOS
- Innovative Reports on the Effects of Anabolic Androgenic Steroid Abuse—How to Lose Your Mind for the Love of Sport
- How to Choose the Optimal Starting Dose of Clomiphene Citrate (50 or 100 mg per Day) for a First Cycle of Ovulation Induction in Anovulatory PCOS Women?
- Melatonin regulates the periodic growth of secondary hair follicles through the nuclear receptor RORα
- Peripubertal Testosterone, 17β-Estradiol and Progesterone Concentrations in Hair and Nails in Dobermann Dogs
- Effect of Neurosteroids on Basal and Stress-Induced Oxytocin Secretion in Luteal-Phase and Pregnant Sheep
- Endocrinology
- Insights into the Scenario of SARS-CoV-2 Infection in Male Reproductive Toxicity
- Landing Eyes on Unnoticed Disorder: A Polycystic Ovary Syndrome
- Polycystic ovary syndrome: Diagnosis and management
- A Case of Successful Treatment with Unilateral Oophorectomy in a Patient with Resistant Polycystic Ovary Syndrome
- Acne associated gynecological diseases and risk factors in the multiethnic women
- Female pattern hair loss: therapeutic update
- Hyperandrogenic eumenorrheic NON-PCOS women versus women with PCOS after the GnRH-agonist stimulation test preceded by suppression of adrenal steroidogenesis with dexamethasone
- (PNM-35) Recurrent priapism in a sickle cell disease patient treated with gonadotropin-releasing hormone (GnRH) agonists drugs: a case report
- Affect of a six months treatment regiment of metformin (MET) on 17-hydroxyprogesterone (17P) responses to GnRH agonist (GnRH Ag) in polycystic ovary syndrome (PCOS)
- Invasion and increased expression of S100A4 and CYR61 in mesenchymal transformed breast cancer cells is downregulated by GnRH
- DIAGNOSTIC AND THERAPEUTIC UTILITY OF GONADOTROPHIN-RELEASING HORMONE AGONIST IN POSTMENOPAUSAL HYPERANDROGENISM OF OVARIAN ORIGIN
- Clinical and Hormonal Effects of Chronic Gonadotropin Releasing Hormone Agonist Treatment in Polycystic Ovarian Disease*
- Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission
- Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5<i>α</i>-Reductase Activity and Androgen Receptor Content*
- Treatment of Hirsutism with a Gonadotropin-Releasing Hormone Agonist (Nafarelin)∗
- Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism.
- Differential Suppression of Testosterone and Estradiol in Hirsute Women With the Superactive Gonadotropin-Releasing Hormone Agonist Leuprolide*
- Gonadotropin-Releasing Hormone Agonist Treatment in Postmenopausal Women with Hyperandrogenism of Ovarian Origin
- Gonadotropin releasing hormone agonist (nafarelin) test to differentiate gonadotropin deficiency from constitutionally delayed puberty in teen-age boys--a clinical research center study.
- A comparative study of a gonadotropin-releasing hormone agonist and finasteride on idiopathic hirsutism.
- Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study.
- Treatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy